{"content":"<li class=\"n-box-item date-title\" data-end=\"1462075199\" data-start=\"1461988800\" data-txt=\"Sunday, December 22, 2019\">Saturday, April 30, 2016</li><li class=\"n-box-item sa-box-item\" data-id=\"3177910\" data-ts=\"1462068057\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACAD\" target=\"_blank\">ACAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3177910-fda-oks-acadia-pharmas-nuplazid-for-pd-psychosis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs ACADIA Pharma&#39;s Nuplazid for PD psychosis</a></h4><ul>\n<li>The FDA approves ACADIA Pharmaceuticals' (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ACAD\" title=\"ACADIA Pharmaceuticals Inc.\">ACAD</a>) Breakthrough Therapy-tagged NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease (PD) psychosis, the first medication OK'd by the agency for the indication.</li>\n<li>\n<a href=\"http://www.acadia-pharm.com/pipeline/nuplazid-pdp/\" target=\"_blank\">NUPLAZID </a>is a non-dopaminergic antipsychotic that acts as a selective serotonin inverse agonist that preferentially targets <a href=\"https://en.wikipedia.org/wiki/5-HT2A_receptor\" target=\"_blank\">5-HT2A receptors</a> while avoiding activity at common targets like dopamine.</li>\n<li>About 40% of the 1M Americans with PD have psychosis, characterized by hallucinations and delusions, diminished quality of life and significant caregiver burden.</li>\n<li>The approval is a big win for the company considering its New Drug Application (NDA) was supported by only one successful Phase 3 study (ACP-103-020). The data package included results from three other trials, but none met the primary endpoint. Normally, the FDA requires two studies to prove efficacy.</li>\n<li>Management will host a conference call on Monday, May 2 at 8:30 am ET to discuss the approval. The U.S. market launch will commence in June.</li>\n<li>Read now <a href=\"https://seekingalpha.com/article/3964961-acadia-approval-likely-parkinsons-disease-psychosis-drug\" target=\"_blank\">Acadia: Approval Likely For Parkinson's Disease Psychosis Drug </a>\n</li>\n<li>\n<strong>Update</strong>: Shares are up <font color=\"green\">7%</font> premarket on increased volume.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3177910\" data-linked=\"FDA OKs ACADIA Pharma&#39;s Nuplazid for PD psychosis\" data-tweet=\"$ACAD - FDA OKs ACADIA Pharma&#39;s Nuplazid for PD psychosis https://seekingalpha.com/news/3177910-fda-oks-acadia-pharmas-nuplazid-for-pd-psychosis?source=tweet\" data-url=\"https://seekingalpha.com/news/3177910-fda-oks-acadia-pharmas-nuplazid-for-pd-psychosis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>86&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":1,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}